Zoetis Inc (ZTS)
InfravaloradaFundamental
72
Precio
$69.89
Capitalización Bursátil
$29.52B
Parte 1 · Cuánto vale la empresa
Resumen
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$9.53B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$2.64B
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$2.28B
Patrimonio Neto Total
$3.42B
Pasivo Total
$12.07B
Ratio de Liquidez
3.08
Cobertura de Intereses
-
Deuda/EBITDA
2.27
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$112.17
Precio Actual
$69.89
Margen de Seguridad
+37.7%
Rango de Valor Justo
$72.91 - $151.42
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
11.29
ROE
78.3%
Ratio P/B
9.07
P/FCF
12.33
Margen Bruto
71.7%
ROIC
-
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
-
WACC
6.8%
ROIC − WACC
-
Criterios de Análisis Fundamental
Superado (18)
- EPS shows upward trend
- EPS CAGR 19.62%
- Gross Margin 71.7%
- P/FCF 12.33
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 69.3%
- Revenue Growth 5Y 7.2%
- Analyst Consensus 50% Buy
- PEG Ratio 0.93
- Earnings Quality (OCF/NI) 1.08
- Share Dilution -2.3%
- Net Margin Trend 27.7% vs 27.6%
- Piotroski F-Score 6/9
Fallido (6)
- Price CAGR 3.15%
- P/B Ratio 9.07
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.5%
No disponible (4)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Ms. Kristin C. Peck | CEO & Director | 54 |
| Ms. Roxanne Lagano | Executive VP, General Counsel & Corporate Secretary | 60 |
| Mr. Wetteny N. Joseph CPA | Special Advisor to the CEO | 53 |
| Dr. Robert J. Polzer Ph.D. | Scientific Advisor | 56 |
| Mr. Jamie Brannan | Executive VP & Chief Commercial Officer | 52 |
| Mr. James K. Saccaro | Executive VP, CFO & COO | 52 |
| Mr. Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | 46 |
| Mr. Steven Frank | Vice President of Investor Relations | - |
| Ms. Julie A. Fuller | Executive VP, Chief Human Resources Officer & Global Operations | 52 |
| Mr. Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations | 37 |
Riesgo de Auditoría
5
Riesgo del Consejo
2
Riesgo de Compensación
6
Riesgo de Derechos del Accionista
7
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-12
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-06
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-08-06
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for ZTS, sourced from Markets Gazette.
- 5/10/2026NEGATIVEZoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?
Zoetis Inc. was among the top large-cap decliners last week, experiencing a significant sell-off. This downturn was primarily attributed to weak earnings reports, cautious forward guidance from the company, and subsequent reductions in analyst price targets. The broader market sentiment also played a role, with declines seen across healthcare, software, networking, and industrial sectors. Investors are advised to monitor Zoetis's upcoming earnings calls and management commentary for signs of a potential turnaround or further headwinds.
via Markets Gazette